Psychedelics Market

Bill passed: wide range of psychedelics could be made legal in the US

Finfeed Archived Jun 03, 2021

In what is a major development for Creso Pharma (ASX: CPH), target acquisition company Halucencex Life Sciences is fast tracking its go to market strategy in California. This follows the recent passing of Senate Bill 519 through the California State Senate, which if signed into law, would make a wide range of psychedelic substances including psilocybin legal to use and possess for adults over the age of 21.

CPH further derisks acquisition as Halucenex adds to its psychedelics supply

Finfeed Archived May 14, 2021

Creso Pharma Limited (ASX: CPH, FRA:1X8) target acquisition company Halucenex Life Sciences has nearly doubled its supply of synthetic psilocybin. Halucenex has secured an additional 10 grams of synthetic psilocybin from its manufacturing partner – Canada’s only pharmaceutical grade synthetic psilocybin producer.

Halucenex forms important partnership as psychedelics space heats

Finfeed Archived May 06, 2021

Creso Pharma Limited (ASX: CPH, FRA:1X8) has today announced that its acquisition target Halucenex Life Sciences Inc. has signed an agreement with Nucro-Technics, a Pharmaceutical Contract Research Organization (CRO) that is a partner to pharmaceutical, biologic, and medical device companies located all over the world.

Revenues up 237%: Creso Pharma delivers strong quarter ahead of OTC listing

Finfeed Archived Apr 30, 2021

There were several highlights to come out of the quarterly report released by Creso Pharma (ASX: CPH) today. CPH is enjoying a sustained run this year with revenues up 237% in the lead up to its US listing, which is expected to occur in the coming weeks.

Move to legalisation of psychedelics could benefit CPH in the US

Finfeed Archived Apr 19, 2021

Creso Pharma Limited’s (ASX:CPH, FRA:1X8) target acquisition company Halucencex Life Sciences Inc. has signed a non-binding Letter of Intent (LOI) with leading nanotechnology company Sixth Wave Inc. as California pushes to decriminalise psychedelics, which highlights the ongoing acceptance and regulatory shift towards psychedelics as an alternative treatment route for debilitating mental health conditions.

Halucenex agreement to give CPH another leg up in psychedelics

Finfeed Archived Mar 31, 2021

Creso Pharma’s (ASX: CPH) pending acquisition of Halucenex Life Sciences should prove to be an astute move, with Halucenex continuing to rapidly move towards its goal of developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets.

We Participated in the CPH placement - and so did Billionaire John Hancock

Next Investors Mar 26, 2021

Creso Pharma (ASX: CPH) is edging closer to becoming part of our long term portfolio. CPH just raised $18M, which significantly shores up the balance sheet - another tick in the box for us as CPH builds trust to enter our long term portfolio.

CPH to list on the OTC as it expands North American footprint

Finfeed Archived Mar 23, 2021

Creso Pharma (ASX: CPH) today announced it is listing on the OTC market in the USA. Listing on the OTC is expected to unlock significant shareholder value and provides CPH with access to one of the largest investment markets in the world at nominal cost.

$15M grant for psychedelics studies as calls to combat mental health intensify

Finfeed Archived Mar 18, 2021

Australia’s federal government will grant $15M to clinical studies that explore the use of psychedelic drugs like magic mushrooms and ecstasy, to treat Australians with debilitating mental illnesses.

Creso Pharma set to be the first ASX listed entrant in new market

Finfeed Archived Mar 15, 2021

Creso Pharma Limited (ASX:CPH, FRA:1X8) has signed an agreement to acquire Halucenex Life Sciences Inc. (Halucenex), an established psychedelics company focused on developing treatments for Treatment Resistant Depression in individuals suffering from PTSD, and other mental health illnesses.

CPH to be the First ASX Stock to Acquire 100% of a Psychedelics Company

Next Investors Mar 15, 2021

Creso Pharma (ASX: CPH) will be the first ASX listed stock to acquire 100% of a psychedelics company. CPH is set to acquire Canada based Halucenex Life Sciences Inc., an established psychedelics company developing treatments for a range of mental illnesses.